Literature DB >> 10219712

Matrix metalloproteinases and their inhibitors in tumour growth and invasion.

V M Kähäri1, U Saarialho-Kere.   

Abstract

Controlled degradation of the extracellular matrix (ECM) is crucial for the growth, invasive capacity, metastasis and angiogenesis of tumours. Matrix metalloproteinases (MMPs), a family of zinc-dependent neutral endopeptidases that are collectively capable of degrading essentially all ECM components, apparently play an important role in all of these aspects of tumour development. In addition, there is recent evidence that MMPs are also important for tumour cell survival. At present, therapeutic intervention on tumour growth and invasion based on the inhibition of MMP activity is under intensive investigation, and several MMP inhibitors are already being used on malignant tumours of various organs in clinical trials. In this review we discuss the role of MMPs and their inhibitors in tumour invasion as a basis for prognostic purposes and for targeted therapeutic intervention in cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10219712     DOI: 10.3109/07853899909019260

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  81 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Expression and distribution of matrix metalloproteinases and their inhibitors in the human iris and ciliary body.

Authors:  J Lan; R K Kumar; N Di Girolamo; P McCluskey; D Wakefield
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

Review 3.  Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch.

Authors:  Tom P Theruvath; Jeffrey A Jones; John S Ikonomidis
Journal:  J Card Surg       Date:  2011-09-29       Impact factor: 1.620

Review 4.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

5.  Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma.

Authors:  Zhiqiang Xia; Wenqing Liu; Shengdong Li; Ge Jia; Yuqi Zhang; Chunde Li; Zhenyu Ma; Jihui Tian; Jian Gong
Journal:  Neurochem Res       Date:  2011-08-04       Impact factor: 3.996

6.  Tear fluid levels of MMP-8 are elevated in ocular rosacea--treatment effect of oral doxycycline.

Authors:  Marko Määttä; Osmo Kari; Taina Tervahartiala; Sirje Peltonen; Marjatta Kari; Matti Saari; Timo Sorsa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

7.  Human aqueous humor levels of transforming growth factor-β2: Association with matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases.

Authors:  Yan Jia; Yu Yue; Dan-Ning Hu; Ji-Li Chen; Ji-Bo Zhou
Journal:  Biomed Rep       Date:  2017-10-20

8.  Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridisation.

Authors:  M T Salmela; T T MacDonald; D Black; B Irvine; T Zhuma; U Saarialho-Kere; S L F Pender
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

9.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

10.  Matrix metalloproteinase-3 accelerates wound healing following dental pulp injury.

Authors:  Li Zheng; Kazuharu Amano; Koichiro Iohara; Masataka Ito; Kiyomi Imabayashi; Takeshi Into; Kenji Matsushita; Hiroshi Nakamura; Misako Nakashima
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.